Sinocare (SHE:300298), through its unit Sino Bio (Hong Kong), signed a distribution agreement with Italian healthcare Menarini Diagnostics, according to a Shenzhen Stock Exchange filing on Tuesday.
A. Menarini Diagnostics will exclusively distribute the Chinese medical device manufacturer's first-generation and second-generation continuous glucose monitoring systems or the iCan CGM System in Europe.
The contract is valid for seven years, but it can be renewed every five years, the disclosure said.
Sinocare's shares jumped less than 3% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。